A fundamental question is whether the IFN-related signature in HSPCs acts as the initiator of disease phenotype, or it is a secondary effect that further amplifies the cascade of events that characterize SLE-dependent inflammation. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.